YOLFTbeta
ToolGen Inc.

ToolGen Inc.

199800 · KQ · Healthcare / Biotechnology

29,250.00KRW-250.00 (-0.85%)

Price History

Full chart

Market Stats

Previous Close29,500.00
Open29,200.00
Day Range28,500.00 – 30,400.00
52-Week Range30,150.00 – 142,000.00
Volume11.94K
Market Cap354.73B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.17
50-Day Avg36,347.00
200-Day Avg53,549.25

About

ToolGen Incorporated, a biotechnology company, focuses on the development of genome editing technology in South Korea. The company develops clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene scissors for gene editing in eukaryotic cells. It is involved in patent monetization, treatment, and seed businesses. ToolGen Incorporated was founded in 1999 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Young Ho Kim
  • Employees80
  • Headquarters172 Magokjungang-ro, Seoul, South Korea, Korea
  • Websitehttps://www.toolgen.com

Leadership

  • Joon Lee JungResearch Head of Platform Development Team
  • Mr. Young Ho KimCEO & Chairman of the Board · b. 1969
  • Mr. Jong Sang RyuCEO
  • Mr. Jin-Soo KimCo-Founder & Member of The Board of Directors · b. 1957
  • Jang HyeopExecutive Director & CFO
  • Lee Baek-seungVice President & CTO
  • Mr. Dave Boncheun KooExecutive VP, Head of IP Business Division & Chief Legal Officer
  • Soon Il KwonHead of Seed Research 1 Division
  • Jae young LeeHead of Therapeutic Development
  • Hyun Young KooHead of Business Development Division

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.54B3.34B1.16B1.13B713.09M1.60B743.46M1.10B890.96M1.31B
Growth (%)-+116.74%-65.35%-2.75%-36.62%+123.99%-53.45%+48.41%-19.25%+46.63%
Cost of Revenue658.08M436.32M386.03M442.84M351.52M510.87M185.06M168.45M217.93M166.59M
Gross Profit882.18M2.90B770.80M682.22M361.58M1.09B558.40M934.96M673.03M1.14B
Gross Margin57.27%86.93%66.63%60.64%50.71%68.02%75.11%84.73%75.54%87.25%
Operating Expense4.15B6.96B9.10B16.82B15.33B21.83B19.94B18.08B22.47B24.42B
Operating Income-3.26B-4.06B-8.33B-16.13B-14.97B-20.74B-19.39B-17.15B-21.80B-23.28B
Operating Margin-211.95%-121.70%-720.21%-1434.11%-2098.70%-1298.45%-2607.48%-1553.88%-2446.62%-1782.04%
EBITDA-------17.07B-40.37B10.65B-33.90B
EBITDA Margin-------2296.49%-3658.68%1194.97%-2595.18%
Net Income-3.02B-4.34B-8.06B-15.78B-14.88B-20.69B-18.18B-42.34B6.23B-36.76B
Net Income Margin-195.85%-130.09%-696.46%-1402.71%-2086.95%-1295.49%-2444.93%-3837.21%699.45%-2814.07%
R&D----4.20B5.45B6.30B6.75B6.84B7.15B
R&D as % of Total Revenue----589.17%341.07%846.86%611.51%767.62%547.57%
Interest Expense000032.19M29.25M28.38M428.25M2.58B1.08B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%4.51%1.83%3.82%38.81%289.75%82.97%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.28B15.16B38.74B29.87B32.41B87.62B75.43B93.45B75.48B61.65B
Total Liabilities1.39B2.17B1.75B3.10B2.52B2.95B4.96B63.36B17.04B5.80B
Total Equity16.89B12.99B36.99B26.77B29.89B84.66B70.47B30.09B58.44B55.85B
Cash---1.55M1.02M2.35M16.16B34.51B16.43B9.48B
Total Debt---43.09M60.67M-----
Net Debt-------25.81B--

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.36B-1.79B-6.29B-9.97B-10.07B-14.83B-14.99B-14.91B-16.46B-20.22B
Investing Cash Flow-6.40B3.70B-24.89B15.93B5.43B-57.98B17.61B-716.21M-2.59B-
Financing Cash Flow10.03B185.80M29.75B1.12B10.86B70.60B887.51M33.96B810.89M-
Capital Expenditure273.98M3.29B434.72M801.58M2.37B617.70M5.38B6.68B534.90M451.25M
Free Cash Flow-----12.44B-15.45B-20.37B-21.59B-16.99B-20.67B
FCF to OCF----123.57%104.17%135.91%144.84%103.25%102.23%

Earnings

Report DateDec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------
EPS Actual-704.39-563.23-442.85-696.87-573.04-472.33-378.87-502.11-3908.86-615.38-766.49-639.862783.93-511.01-504.75-624.80-2466.28-482.98-741.67
Surprise-------------------
Timing-------------------

Key Statistics & Ratios

Market Cap354.73B
Enterprise Value289.76B
Trailing P/E0.00
Forward P/E0.00
Price / Sales194.12
Price / Book6.64
Revenue (TTM)1.83B
Gross Profit (TTM)1.65B
EBITDA-22.11B
Profit Margin0.00%
Operating Margin-1414.51%
Return on Equity-77.38%
Return on Assets-24.02%
Shares Outstanding9.77M
Shares Float7.23M
Beta1.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%